KCNK2

Potassium channel subfamily K member 2 · O95069 · KCNK2 on Sugi Atlas →

15,299 patent compounds predicted against KCNK2, 10,636 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1025150	0.49	11/20
SCHEMBL1015553	0.57	10/20
SCHEMBL1160810	0.47	8/20
SCHEMBL503539	0.39	5/20
SCHEMBL1466665	0.58	4/20
SCHEMBL381447	0.45	4/20
SCHEMBL696549	0.37	4/20
SCHEMBL485586	0.36	4/20
SCHEMBL518852	0.42	3/20
SCHEMBL484994	0.38	3/20
SCHEMBL1231549	0.35	3/20
SCHEMBL1546684	0.35	3/20
Fluoxetine (SCHEMBL8353)	1.00	2/20
Fluoxetine (SCHEMBL33947)	1.00	2/20
Z-Flupentixol (SCHEMBL34200)	1.00	2/20
E-Flupentixol (SCHEMBL145726)	1.00	2/20
Seproxetine (SCHEMBL272873)	1.00	2/20
E-Flupentixol (SCHEMBL414352)	1.00	2/20
Fluoxetine (SCHEMBL570572)	1.00	2/20
Norfluoxetine (SCHEMBL686500)	1.00	2/20

Clinical trials — most relevant to KCNK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Sandostatine® LP and Hyperinsulinism	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet	PHASE1	NOT_YET_RECRUITING
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Peripheral KV7 Activation for Pain Relief	EARLY_PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk	nan	COMPLETED
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
CNKSR2 Natural History Study	nan	RECRUITING
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients	nan	UNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
The Genetic Basis of Atrial Fibrillation (AF)	nan	COMPLETED
Clinical Phenotype and Omics Study of KCNQ2-related Epilepsy	nan	UNKNOWN
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KCNK2 binder may also engage these)

Protein	Name	Similarity
Q920B6	—	1.000	Q920B6 →
P97438	—	1.000	P97438 →
KCNK10	Potassium channel subfamily K member 10	0.996	landscape →
Q8BUW1	—	0.996	Q8BUW1 →
P34410	—	0.993	P34410 →
Q9JIS4	—	0.991	Q9JIS4 →
Q3LS21	—	0.990	Q3LS21 →
KCNK9	Potassium channel subfamily K member 9	0.989	landscape →
Q9JL58	—	0.989	Q9JL58 →
O17185	—	0.988	O17185 →
Q622X0	—	0.987	Q622X0 →
KCNK3	Potassium channel subfamily K member 3	0.987	landscape →
O00180	—	0.986	O00180 →
SLC8A1	Sodium/calcium exchanger 1	0.986	landscape →
P40310	—	0.986	P40310 →
Q5UE96	—	0.986	Q5UE96 →
Q22271	—	0.985	Q22271 →
KCNA1	Potassium voltage-gated channel subfamily A member 1	0.985	landscape →
Q9ES08	—	0.985	Q9ES08 →
P48765	—	0.984	P48765 →
Q18120	—	0.984	Q18120 →
Q63ZI0	—	0.984	Q63ZI0 →
Q7T199	—	0.984	Q7T199 →
P63142	—	0.984	P63142 →
P63141	—	0.984	P63141 →
KCNA2	Potassium voltage-gated channel subfamily A member 2	0.984	landscape →
B2RQA1	—	0.984	B2RQA1 →
Q9I830	—	0.984	Q9I830 →
P97414	—	0.984	P97414 →
Q9QUQ5	—	0.984	Q9QUQ5 →